More on Watson Pharma (WPI +2.1%) Q1: Net income +21% to $54.8M, with earnings boosted by...
More on Watson Pharma (WPI +2.1%) Q1: Net income +21% to $54.8M, with earnings boosted by Watson's generic versions of the Lipitor cholesterol drug and Lovenox blood thinner, and a rise in international sales. 2012 guidance: adjusted EPS $5.55-$5.80 and revenue $5.5B vs. consensus of $5.80 and $5.5B.
From other sites
Video at CNBC.com (Mon, 11:40AM)
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
at CNBC.com (Feb 5, 2015)
at CNBC.com (Jan 30, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs